Simulation Study when Data are MAR Clause Samples

Simulation Study when Data are MAR. In this section, we provide three simulation studies to demonstrate our privacy-preserving methods in comparison with the standard methods of addressing missing data under univariate and general missing data patterns. As in Section 3.2, we consider a linear regression model (3.1) as the “analysis model”. The simulation results over 1000 Monte Carlo(MC) data sets. Each simulation study has a different way to generate the MC data sets. In the first study, we explore approaches for addressing continuous variable with miss- ing values under univariate missing data patterns, i.e. only X1 has missing values. Data X1, ..., Xp and Y are generated for n = 200 and n = 1000 individuals. We consider a setting with p = 2 in this study. For each individual, X2 is first generated from a uniform distribution U (−1, 1). Given X2, variable X1 is sampled from a normal dis- X1 tribution with variance σ2 = 1 and mean µX1 = X2. Outcome Y is generated from Y = θ0 + θ1X1 + θ2X2 + s, where s ∼ N (0, 1) and all θj = 1 (j = 0, 1, 2). Variable X1 is missing with probability {1 + exp(1.6 − Y − X2)}−1, resulting in approximately 42% of individuals having missing values. In order to illustrate that our privacy-preserving methods can be applied to binary variable with missing values, we make a little change to the previous data-generating mechanism. Given X2, instead of sampling X1 from a normal distribution, we generate X1 from a Bernoulli distribution with probability {1 + exp(−1 − X2)}−1. The rest procedures are the same.
View Source

Related to Simulation Study when Data are MAR

  • Programming Phase Schematic Design Phase: 2.2.1.3. Design Development Phase:

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Preparatory Contract Negotiations Meetings Where operational requirements permit, the Employer will grant leave without pay to an employee to attend preparatory contract negotiations meetings.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.